Stock listing
NASDAQ:AGMB AgomAb Therapeutics NV Stock
Follow AgomAb Therapeutics NV into a list and get an email when it puts out news.
Share price · NASDAQ:AGMB
$5.45 USD -0.37 (-6.4%)
Close on Nov 20, 2026
- Day range
- $5.39 – $5.78 USDNov 20, 2026
- Volume
- 188,938 sharesNov 20, 2026
- Market cap
- $268.4M USDAt the close on Nov 20, 2026 · price × 49.25M shares outstanding
- Traded on an average day
- $1.91M USDMedian day 129,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AGMB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.45 | -0.37 | -6.4% | $5.51 | $5.78 | $5.39 | 188,938 | |
| $5.82 | -0.10 | -1.7% | $6.00 | $6.25 | $5.70 | 131,857 | |
| $5.92 | -0.05 | -0.8% | $6.00 | $6.435 | $5.50 | 296,439 | |
| $5.97 | -0.39 | -6.1% | $6.36 | $6.505 | $5.90 | 165,616 | |
| $6.36 | 0.00 | 0.0% | $6.32 | $6.605 | $5.731 | 192,639 | |
| $6.36 | -0.63 | -9.0% | $6.90 | $6.98 | $6.19 | 1,517,921 | |
| $6.99 | 0.00 | 0.0% | $7.07 | $7.23 | $6.85 | 433,254 | |
| $6.99 | -0.56 | -7.4% | $7.54 | $7.75 | $6.80 | 447,059 | |
| $7.55 | -0.085 | -1.1% | $7.72 | $8.245 | $7.32 | 661,382 | |
| $7.635 | +0.665 | +9.5% | $7.09 | $8.15 | $7.005 | 158,411 | |
| $6.97 | +0.12 | +1.8% | $6.85 | $7.46 | $6.47 | 780,328 | |
| $6.85 | 0.00 | 0.0% | $7.00 | $7.085 | $6.76 | 79,984 | |
| $6.85 | +0.13 | +1.9% | $6.67 | $7.155 | $6.67 | 40,243 | |
| $6.72 | -0.77 | -10.3% | $7.57 | $8.111 | $6.548 | 105,630 | |
| $7.49 | -0.46 | -5.8% | $7.00 | $7.955 | $6.61 | 197,833 | |
| $7.95 | -0.01 | -0.1% | $7.98 | $8.292 | $7.47 | 575,393 | |
| $7.96 | -0.44 | -5.2% | $8.37 | $8.37 | $7.71 | 105,583 | |
| $8.40 | -0.17 | -2.0% | $8.60 | $8.60 | $7.88 | 89,797 | |
| $8.57 | -0.48 | -5.3% | $9.10 | $9.33 | $8.44 | 73,647 | |
| $9.05 | -0.21 | -2.3% | $9.15 | $9.184 | $8.675 | 49,125 | |
| $9.26 | +0.15 | +1.6% | $9.15 | $9.44 | $8.90 | 84,322 | |
| $9.11 | +0.38 | +4.4% | $8.74 | $9.22 | $8.74 | 42,422 | |
| $8.73 | +0.50 | +6.1% | $8.24 | $8.97 | $8.23 | 35,303 | |
| $8.23 | -0.05 | -0.6% | $8.28 | $8.61 | $8.16 | 31,092 | |
| $8.28 | -0.05 | -0.6% | $8.21 | $8.53 | $7.92 | 78,133 | |
| $8.33 | -0.36 | -4.1% | $8.56 | $8.86 | $8.15 | 97,715 | |
| $8.69 | -0.12 | -1.4% | $8.80 | $9.08 | $8.51 | 57,697 | |
| $8.81 | -0.28 | -3.1% | $9.05 | $9.35 | $8.73 | 59,400 | |
| $9.09 | +0.01 | +0.1% | $9.18 | $9.65 | $9.05 | 62,300 | |
| $9.08 | -0.14 | -1.5% | $9.36 | $9.49 | $8.92 | 102,100 | |
| $9.22 | +0.42 | +4.8% | $8.88 | $9.45 | $8.56 | 225,200 | |
| $8.80 | -0.04 | -0.5% | $8.95 | $9.35 | $8.68 | 104,900 | |
| $8.84 | +0.15 | +1.7% | $8.77 | $8.97 | $8.40 | 103,900 | |
| $8.69 | +0.13 | +1.5% | $8.51 | $8.71 | $7.97 | 129,600 | |
| $8.56 | -0.09 | -1.0% | $8.65 | $9.34 | $8.00 | 388,700 | |
| $8.65 | -2.45 | -22.1% | $11.21 | $11.32 | $8.56 | 639,200 | |
| $11.10 | +0.57 | +5.4% | $10.62 | $11.36 | $10.58 | 133,700 | |
| $10.53 | +0.32 | +3.1% | $10.23 | $10.69 | $10.14 | 113,500 | |
| $10.21 | -0.30 | -2.9% | $10.51 | $10.54 | $9.87 | 147,200 | |
| $10.51 | -0.07 | -0.7% | $10.65 | $11.23 | $10.41 | 164,000 | |
| $10.58 | -0.19 | -1.8% | $10.75 | $10.99 | $10.50 | 64,200 | |
| $10.77 | -0.72 | -6.3% | $11.54 | $11.80 | $10.64 | 98,700 | |
| $11.49 | -0.21 | -1.8% | $11.70 | $11.85 | $11.31 | 49,400 | |
| $11.70 | -0.47 | -3.9% | $12.26 | $12.26 | $11.28 | 85,400 | |
| $12.17 | +0.09 | +0.7% | $12.26 | $12.99 | $11.60 | 250,700 | |
| $12.08 | +0.67 | +5.9% | $11.66 | $12.46 | $11.62 | 339,300 | |
| $11.41 | -0.75 | -6.2% | $12.26 | $12.85 | $11.21 | 120,300 | |
| $12.16 | -0.12 | -1.0% | $12.31 | $12.92 | $11.61 | 146,300 | |
| $12.28 | -0.78 | -6.0% | $13.20 | $13.29 | $12.20 | 86,200 | |
| $13.06 | -0.88 | -6.3% | $14.00 | $14.10 | $12.96 | 196,700 | |
| $13.94 | -1.02 | -6.8% | $14.91 | $16.40 | $13.75 | 106,700 | |
| $14.96 | +0.05 | +0.3% | $14.94 | $15.70 | $14.65 | 72,600 | |
| $14.91 | -0.87 | -5.5% | $15.78 | $16.50 | $14.51 | 260,600 | |
| $15.78 | +0.95 | +6.4% | $14.83 | $15.86 | $14.53 | 245,300 | |
| $14.83 | +1.17 | +8.6% | $13.67 | $14.94 | $13.59 | 407,900 | |
| $13.66 | +0.12 | +0.9% | $13.29 | $13.96 | $13.19 | 158,900 | |
| $13.54 | +0.37 | +2.8% | $12.90 | $13.99 | $12.62 | 241,300 | |
| $13.17 | 0.00 | 0.0% | $13.15 | $14.13 | $12.75 | 105,400 | |
| $13.17 | -0.67 | -4.8% | $13.84 | $14.20 | $12.84 | 252,900 | |
| $13.84 | -0.44 | -3.1% | $14.26 | $14.37 | $13.66 | 154,200 | |
| $14.28 | +0.26 | +1.9% | $14.19 | $14.60 | $13.58 | 243,700 | |
| $14.02 | +1.20 | +9.4% | $13.40 | $14.26 | $13.16 | 219,354 | |
| $12.82 | -0.43 | -3.2% | $13.21 | $13.23 | $12.76 | 31,651 | |
| $13.25 | -0.18 | -1.3% | $13.50 | $13.64 | $13.07 | 68,400 | |
| $13.43 | -0.32 | -2.3% | $13.74 | $13.85 | $13.01 | 92,200 |
- Ticker
- NASDAQ:AGMB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Agomab to Participate in Upcoming Investor Conferences
Latest deck · Oct 1, 2026
Investor Presentation (October 2026)
Investor deck · 29 slides
Latest news
Agomab to Participate in Upcoming Investor Conferences
Nov 4, 2026
Closed $6.97 (+1.8%) on Nov 5, 2026
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Oct 13, 2026
Closed $8.69 (-1.4%) on Oct 14, 2026
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
Oct 8, 2026
Closed $9.08 (-1.5%) on Oct 9, 2026
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
Oct 1, 2026
Closed $8.65 (-22.1%) on Oct 1, 2026
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Sep 14, 2026
Closed $12.16 (-1.0%) on Sep 15, 2026
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Sep 11, 2026
Closed $12.28 (-6.0%) on Sep 14, 2026
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Aug 6, 2026
Closed $14.50 (+7.4%) on Aug 7, 2026
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Jun 23, 2026
Closed $12.68 (+6.2%) on Jun 24, 2026
Agomab Announces Results of Annual General Meeting
May 27, 2026
Closed $11.67 (+5.6%) on May 27, 2026
Agomab to Participate in Upcoming Conferences
May 14, 2026
Closed $11.04 (-1.3%) on May 14, 2026
AgomAb Therapeutics NV on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 16 in all · newest Nov 4, 2026 · oldest 2026
- Decks
- 2 decks · latest Oct 1, 2026
Valuation
Price/book 0.9× against a median of 2.1×: 2nd lowest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$6.88M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.29
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AgomAb Therapeutics NV · NASDAQ:AGMB | US$268.4M | −US$6.88M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.29 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.1M | US$182.5M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Agenus Inc. · NASDAQ:AGEN | US$270.1M | US$218.3M | 9.2× | 1.6× | 4.0× | n/a | 22.0% | n/a | 1.80 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| Median of the others | US$262.6M | US$175.3M | 9.2× | 37.3× | 4.0× | 2.1× | −112.6% | 0.1× | 1.48 |
Forecasts
4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 37.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.81 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tim Knotnerus | Chief Executive Officer |
| Pierre Kemula | Chief Financial Officer |
| Ellen Lefever | General Counsel |
| Sofie Van Gijsel | VP of Investor Relations |
| Andrea Sáez | Chief Development Officer |
| Paul van der Horst | Chief Business Officer |
| Philippe Wiesel | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| David Epstein | Chairman of the Board |
| Angelika Jahreis | Non-Executive Director |
| Colin Bond | Non-Executive Director and Chairman of the Audit Committee |
| Felice Verduyn | Representing EQT Life Sciences |
| Marino Garcia | Non-Executive Director |
| Naimish Patel | Non-Executive Director |
| Ohad Hammer | Representing Pontifax |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | Apr 24, 2026 | +5.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 29 slides | Oct 1, 2026 |
| Investor Presentation (August 2026) | Investor deck | 50 slides | August 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of american Depositary Shares Closed: US$200M raised · US$16 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Leerink Partners (co-lead), Van Lanschot Kempen (co-lead) | Feb 9, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 an ADS on Feb 5, 2026.
- Price
- US$16.00 an ADS
- Offering size
- US$200 million
- Underwriters' option
- Up to 1,875,000 more ADSs
- Listing
- AGMB on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 20, 2024 |
| Filed publicly | Jan 16, 2026 |
| Amended once | Jan 29, 2026 |
| Declared effective by the SEC | Jan 30, 2026 |
| Shares registered with an exchange | Feb 3, 2026 |
| Final prospectus, with the price | Feb 6, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 6, 2026 |
| CERT · Exchange's certificate of listing | Feb 5, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 3, 2026 |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 |
| F-1/A · Registration statement, amended | Jan 29, 2026 |
| F-1 · Registration statement | Jan 16, 2026 |
| DRS/A · Draft registration statement, amended | Dec 17, 2025 |
| DRS/A · Draft registration statement, amended | Oct 28, 2025 |
| DRS · Draft registration statement | Jun 20, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2026
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of revenue | 210.4K | |||
| Gross profit | -210.4K | |||
| Research and development | 48.9M | 39.3M | 26.3M | 19.4M |
| Selling, general and administrative | 12.6M | 9.82M | 6.00M | 4.49M |
| Operating income | -59.3M | -48.0M | -31.2M | -22.6M |
| Depreciation and amortization | 219.0K | 311.0K | 99.0K | 23.0K |
| EBITDA | -59.1M | -47.7M | -31.1M | -22.6M |
| Interest expense | 60.0K | 67.0K | 31.0K | 45.0K |
| Income before tax | -62.5M | -46.3M | -12.0M | -10.8M |
| Income tax | 4.00K | 4.00K | -619.0K | -2.66M |
| Net income | -62.5M | -46.3M | -11.4M | -8.14M |
| Earnings per share, basic | -1.28 | -1.28 | -0.31 | -0.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 86.4M | 171.5M | 122.4M | 27.7M | 53.6M |
| Short-term investments | 30.1M | 0 | 0 | 40.0M | 0 |
| Receivables | 4.78M | ||||
| Current assets | 121.2M | 173.8M | 139.5M | 71.1M | 54.4M |
| Goodwill | 10.1M | 8.61M | 8.61M | 8.61M | 8.61M |
| Total assets | 153.7M | 206.4M | 171.3M | 101.0M | 84.0M |
| Accounts payable | 7.63M | 5.95M | 6.83M | 3.90M | 1.06M |
| Current liabilities | 18.6M | 9.13M | 10.9M | 29.7M | 33.7M |
| Long-term debt | 690.0K | ||||
| Total debt | 1.25M | ||||
| Total liabilities | 22.8M | 18.3M | 19.8M | 34.7M | 41.6M |
| Shareholders' equity | 130.9M | 188.1M | 151.4M | 66.2M | 42.4M |
| Shares outstanding | 48.7M | 36.2M | 36.2M | 36.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -51.7M | -46.8M | -24.6M | -19.0M |
| Capital spending | -4.00K | -675.0K | 0 | 0 |
| Free cash flow | -51.7M | -47.5M | -24.6M | -19.0M |
| Cash from investing | -33.0M | |||
| Cash from financing | -338.0K | 96.8M | 79.3M | 37.6M |
| Change in cash | -85.0M | 49.3M | 94.7M | -25.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
All 52 filings
Cap table
Built by 6ix from AgomAb Therapeutics NV’s releases · as of Feb 9, 2026
- Common shares
- 49,247,975
- Fully diluted
- 49,247,975
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 49,247,975 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 49,247,975 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David R. Epstein Other companies: Tempus AI, Inc. (Director · Since at least Jun 13, 2024); Seagen Inc (CEO, Director · Nov 10, 2023 – Dec 14, 2023 · Past) | Director · Since at least Mar 18, 2026 |
| Marino Garcia Other companies: Dianthus Therapeutics, Inc. (President & Chief Executive Officer, Board Member · Since at least Sep 11, 2023); Synergy Pharmaceuticals Inc (EVP and Chief Strategy Officer · Jan 5, 2018 – Jan 5, 2018 · Past) | Director · Since at least Sep 11, 2026 |
| Naimish Patel Other companies: CRISPR Therapeutics AG (Chief Medical Officer · Since at least Jun 1, 2026) | Non-Executive Director · Since at least Sep 11, 2026 |
| Weegen Felice Isabel Verduyn-van Other companies: Evommune, Inc. (Director · Since at least Nov 5, 2025) | Director · Since at least Mar 18, 2026 |
| Andrea Sáez | Chief Development Officer · Since at least Nov 4, 2026 |
| Andrea Saez Borderias | Chief Development Officer · Since at least Mar 18, 2026 |
| Angelika Jahreis | Non-Executive Director · Since at least Nov 5, 2026 |
| Colin Bond | Director · Since at least Mar 18, 2026 |
| ContactsInvestors Sofie Van Gijsel | VP of Investor RelationsE-mail · May 27, 2026 – Nov 5, 2026 · Past |
| Ellen Lefever | General Counsel · Since at least Mar 18, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Felice Verduyn | Representing EQT Life Sciences · Since at least Nov 5, 2026 |
| Ohad Hammer | Representing Pontifax · Since at least Mar 18, 2026 |
| Paul van der Horst | Chief Business Officer · Since at least Mar 18, 2026 |
| Philippe Wiesel | Chief Medical Officer · Since at least Mar 18, 2026 |
| Pierre Kemula | Chief Financial Officer · Since at least Mar 18, 2026 |
| Sofie Van Gijsel | VP of Investor Relations · Since at least Nov 4, 2026 |
| Tim Knotnerus | Chief Executive Officer · Since at least Sep 11, 2026 |
Log in to ask 6ix AI your own questions about AgomAb Therapeutics NV.